Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Story CM, Wang T, Bhatt VR, Battiwalla M, Badawy SM, Kamoun M, Gragert L, Brown V, Baxter-Lowe LA, Marsh SGE, Gadalla SM, Schetelig J, Mytilineos J, Miklos D, Waller EK, Kuxhausen M, Spellman S, Lee S, Paczesny S, Lansford JL, Vincent BG, Riches ML, Armistead PM. Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther 2021;27:591-599. [PMID: 33882342 DOI: 10.1016/j.jtct.2021.04.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2020] [Revised: 04/06/2021] [Accepted: 04/08/2021] [Indexed: 01/06/2023]

For:	Story CM, Wang T, Bhatt VR, Battiwalla M, Badawy SM, Kamoun M, Gragert L, Brown V, Baxter-Lowe LA, Marsh SGE, Gadalla SM, Schetelig J, Mytilineos J, Miklos D, Waller EK, Kuxhausen M, Spellman S, Lee S, Paczesny S, Lansford JL, Vincent BG, Riches ML, Armistead PM. Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther 2021;27:591-599. [PMID: 33882342 DOI: 10.1016/j.jtct.2021.04.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2020] [Revised: 04/06/2021] [Accepted: 04/08/2021] [Indexed: 01/06/2023]

Number

Cited by Other Article(s)

Cieri N, Hookeri N, Stromhaug K, Li L, Keating J, Díaz-Fernández P, Gómez-García de Soria V, Stevens J, Kfuri-Rubens R, Shao Y, Kooshesh KA, Powell K, Ji H, Hernandez GM, Abelin J, Klaeger S, Forman C, Clauser KR, Sarkizova S, Braun DA, Penter L, Kim HT, Lane WJ, Oliveira G, Kean LS, Li S, Livak KJ, Carr SA, Keskin DB, Muñoz-Calleja C, Ho VT, Ritz J, Soiffer RJ, Neuberg D, Stewart C, Getz G, Wu CJ. Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation. Nat Biotechnol 2024:10.1038/s41587-024-02348-3. [PMID: 39169264 DOI: 10.1038/s41587-024-02348-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2023] [Accepted: 07/02/2024] [Indexed: 08/23/2024]

Affiliation(s)

Nicoletta Cieri Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA Harvard Medical School, Boston, MA, USA
Nidhi Hookeri Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA
Kari Stromhaug Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA
Liang Li Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA
Julia Keating Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA
Paula Díaz-Fernández Department of Immunology, Instituto de Investigación Sanitaria Princesa (IIS-IP), Hospital Universitario de La Princesa, Madrid, Spain
Valle Gómez-García de Soria Department of Hematology, Instituto de Investigación Sanitaria Princesa (IIS-IP), Hospital Universitario de La Princesa, Madrid, Spain
Jonathan Stevens Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA
Raphael Kfuri-Rubens Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA
Yiren Shao Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA
Kameron A Kooshesh Harvard Medical School, Boston, MA, USA
Kaila Powell Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Helen Ji Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Gabrielle M Hernandez Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA
Jennifer Abelin Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA
Susan Klaeger Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA Department of Proteomic and Genomic Technologies, Genentech Inc, South San Francisco, CA, USA
Cleo Forman Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA
Karl R Clauser Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA
Siranush Sarkizova Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA
David A Braun Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA Harvard Medical School, Boston, MA, USA Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA
Livius Penter Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA Harvard Medical School, Boston, MA, USA Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Berlin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
Haesook T Kim Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA
William J Lane Harvard Medical School, Boston, MA, USA Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA
Giacomo Oliveira Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA Harvard Medical School, Boston, MA, USA
Leslie S Kean Harvard Medical School, Boston, MA, USA Division Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA
Shuqiang Li Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA, USA
Kenneth J Livak Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA, USA
Steven A Carr Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA
Derin B Keskin Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA Harvard Medical School, Boston, MA, USA Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA, USA Department of Computer Science, Metropolitan College, Boston University, Boston, MA, USA Section for Bioinformatics, Department of Health Technology, Technical University of Denmark, Lyngby, Denmark
Cecilia Muñoz-Calleja Department of Immunology, Instituto de Investigación Sanitaria Princesa (IIS-IP), Hospital Universitario de La Princesa, Madrid, Spain Department of Medicine, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
Vincent T Ho Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Harvard Medical School, Boston, MA, USA Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
Jerome Ritz Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Harvard Medical School, Boston, MA, USA Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
Robert J Soiffer Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Harvard Medical School, Boston, MA, USA Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
Donna Neuberg Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA
Chip Stewart Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA
Gad Getz Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA Harvard Medical School, Boston, MA, USA Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA Department of Pathology, Massachusetts General Hospital, Boston, MA, USA
Catherine J Wu Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA. Harvard Medical School, Boston, MA, USA. Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.

Collapse

Fuchs KJ, Falkenburg JHF, Griffioen M. Minor histocompatibility antigens to predict, monitor or manipulate GvL and GvHD after allogeneic hematopoietic cell transplantation. Best Pract Res Clin Haematol 2024;37:101555. [PMID: 39098803 DOI: 10.1016/j.beha.2024.101555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2024] [Revised: 04/22/2024] [Accepted: 05/08/2024] [Indexed: 08/06/2024]

Jadi O, Tang H, Olsen K, Vensko S, Zhu Q, Wang Y, Haiman CA, Pooler L, Sheng X, Brock G, Webb A, Pasquini MC, McCarthy PL, Spellman SR, Hahn T, Vincent B, Armistead P, Sucheston-Campbell LE. Associations of minor histocompatibility antigens with outcomes following allogeneic hematopoietic cell transplantation. Am J Hematol 2023;98:940-950. [PMID: 37052167 PMCID: PMC10368187 DOI: 10.1002/ajh.26925] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2023] [Revised: 03/09/2023] [Accepted: 03/23/2023] [Indexed: 04/14/2023]

Abstract

The role of minor histocompatibility antigens (mHAs) in mediating graft versus leukemia and graft versus host disease (GvHD) following allogeneic hematopoietic cell transplantation (alloHCT) is recognized but not well-characterized. By implementing improved methods for mHA prediction in two large patient cohorts, this study aimed to comprehensively explore the role of mHAs in alloHCT by analyzing whether (1) the number of predicted mHAs, or (2) individual mHAs are associated with clinical outcomes. The study population consisted of 2249 donor-recipient pairs treated for acute myeloid leukemia and myelodysplastic syndrome with alloHCT. A Cox proportional hazard model showed that patients with a class I mHA count greater than the population median had an increased hazard of GvHD mortality (hazard ratio [HR] = 1.39, 95% confidence interval [CI] = 1.01, 1.77, p = .046). Competing risk analyses identified the class I mHAs DLRCKYISL (GSTP), WEHGPTSLL (CRISPLD2), and STSPTTNVL (SERPINF2) were associated with increased GVHD mortality (HR = 2.84, 95% CI = 1.52, 5.31, p = .01), decreased leukemia-free survival (LFS) (HR = 1.94, 95% CI = 1.27, 2.95, p = .044), and increased disease-related mortality (DRM) (HR = 2.32, 95% CI = 1.5, 3.6, p = .008), respectively. One class II mHA YQEIAAIPSAGRERQ (TACC2) was associated with increased risk of treatment-related mortality (TRM) (HR = 3.05, 95% CI = 1.75, 5.31, p = .02). WEHGPTSLL and STSPTTNVL were both present within HLA haplotype B*40:01-C*03:04 and showed a positive dose-response relationship with increased all-cause mortality and DRM and decreased LFS, indicating these two mHAs contribute to the risk of mortality in an additive manner. Our study reports the first large-scale investigation of the associations of predicted mHA peptides with clinical outcomes following alloHCT.

Collapse

Affiliation(s)

Othmane Jadi Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB# 7295, Chapel Hill, NC
Hancong Tang College of Pharmacy, The Ohio State University, Columbus, OH
Kelly Olsen Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB# 7295, Chapel Hill, NC
Steven Vensko Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB# 7295, Chapel Hill, NC
Qianqian Zhu Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Yiwen Wang Quantitative Sciences Unit, Department of Medicine, Stanford University, Palo Alto, CA
Christopher A Haiman Department of Preventive Medicine, University of Southern California, Los Angeles, CA
Loreall Pooler The Center for Genetic Epidemiology, University of Southern California, Los Angeles, CA
Xin Sheng Department of Preventive Medicine, University of Southern California, Los Angeles, CA
Guy Brock Department of Biomedical Informatics, The Ohio State University, Columbus, OH
Amy Webb Department of Biomedical Informatics, The Ohio State University, Columbus, OH
Marcelo C. Pasquini Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI
Philip L McCarthy Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Stephen R. Spellman Center for International Blood and Marrow Transplant Research, National Marrow Donor Program, Minneapolis, MN
Theresa Hahn Department of Cancer Prevention & Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Benjamin Vincent Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB# 7295, Chapel Hill, NC Division of Hematology, Department of Medicine, UNC School of Medicine, Chapel Hill, NC
Paul Armistead Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB# 7295, Chapel Hill, NC Division of Hematology, Department of Medicine, UNC School of Medicine, Chapel Hill, NC
Lara E. Sucheston-Campbell College of Pharmacy, The Ohio State University, Columbus, OH College of Veterinary Medicine, The Ohio State University, Columbus, OH

Collapse

Martin PJ, Levine DM, Storer BE, Zheng X, Jain D, Heavner B, Norris BM, Geraghty DE, Spellman SR, Sather CL, Wu F, Hansen JA. A Model of Minor Histocompatibility Antigens in Allogeneic Hematopoietic Cell Transplantation. Front Immunol 2021;12:782152. [PMID: 34868058 PMCID: PMC8636906 DOI: 10.3389/fimmu.2021.782152] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2021] [Accepted: 10/29/2021] [Indexed: 12/02/2022] Open

Giesler S, Zeiser R. Deciphering the role of Minor histocompatibility antigens for acute graft-versus-host disease. Transplant Cell Ther 2021;27:523-524. [PMID: 34210498 DOI: 10.1016/j.jtct.2021.06.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]